MiNK Therapeutics (FRA:6Q40) PB Ratio: (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6Q40 MiNK Therapeutics Inc FRA:6Q40
21 GF Score
Price €9.00
! 2 Warning Signs
View Full Analysis

What is MiNK Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-16), MiNK Therapeutics's share price is €9.00. MiNK Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was €-2.21. Hence, MiNK Therapeutics's PB Ratio of today is .

The historical rank and industry rank for MiNK Therapeutics's PB Ratio or its related term are showing as below:

FRA:6Q40's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.93
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was -194.80% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of MiNK Therapeutics was 78.00% per year. The lowest was -194.80% per year. And the median was 31.70% per year.

Back to Basics: PB Ratio


MiNK Therapeutics  (FRA:6Q40) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


MiNK Therapeutics PB Ratio Related Terms


MiNK Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for MiNK Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics PB Ratio Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

MiNK Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:6Q40 vs BOLD, FLNA, DWTX: PB Ratio Comparison

For the Biotechnology subindustry, MiNK Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MiNK Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's PB Ratio falls into.


FRA:6Q40
21GF Score
MiNK Therapeutics Inc FRA:6Q40
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

MiNK Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=9.00/-2.208
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


MiNK Therapeutics Business Description

Other Exchanges INKT:USA
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
21GF Score

Get the complete analysis for FRA:6Q40

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.00
Price